All times shown are EST.

8:30 am Online Networking Break

8:55 am Chair’s Opening Remarks

ATR & Targeted Replication Stress

9:00 am Targeting DNA Replication Stress Response in Cancer

9:30 am Inhibition of ATR: Progress from the Lab to the Clinic

  • John Pollard Global Head Early Clinical Development & Translational Medicine Oncology, Bayer

10:00 am Randomized Phase 2 Study of ATR inhibitor Berzosertib in Combination with Gemcitabine versus Gemcitabine alone in Platinum Resistant High Grade Serous Ovarian Cancer

10:30 am Online Networking Break

11:00 am Panel Discussion: Evaluating the Safety, Tolerability & Efficacy of ATR

  • Graeme Smith Chief Scientific Officer, Artios Pharma
  • Eric Brown Associate Professor of Cancer Biology, University of Pennsylvania
  • Oren Gilad Chief Executive Officer, Atrin Pharmaceuticals
  • Timothy A. Yap Associate Professor, Investigational Cancer Therapeutics, MD Anderson Cancer Center

Next Generation Synthetic Lethal Interactions

11:45 am Acquired Resistance to PARP Inhibitors Evolves from DrugTolerant Cells Vulnerable to Low Doses of AsiDNA™

12:15 pm Targeting RAD51-Mediated Homologous Recombination as a Novel Therapeutic Approach to Treating Cancer Patients

  • Paul Secrist Chief Scientific Officer, Cyteir Therapeutics

12:45 pm Online Networking Lunch

1:45 pm Discussing the Potential of Pol Theta

2:15 pm Pharmacological inhibition of DNA polymerase theta (Polθ) activity shows promise as novel treatment for homologous recombination deficient tumors

2:45 pm Defective ALC1 Nucleosome Remodeling Confers PARPi Sensitization & Synthetic Lethality in Certain Cancers

  • Simon Boulton Senior Group Leader, Francis Crick Institute Co-founder & VP Science Strategy Artios Pharma,

3:15 pm Targeting Nucleotide Excision Repair (NER) Deficiency in Cancer

  • Kent Mouw Assistant Professor of Radiation Oncology, Dana-Farber Cancer Institute

3:45 pm Online Networking Break

Preclinical Model Systems

4:15 pm Analyzing Tumor Heterogeneity & Preclinical Models to Study Discrete Populations

4:45 pm Panel Discussion: What is the Role of DDR-targeted Therapies in the Wider Oncology Portfolio?

  • John Pollard Global Head Early Clinical Development & Translational Medicine Oncology, Bayer
  • Elisabetta Leo Principal Scientist, AstraZeneca
  • Geoffrey Shapiro Director Early Drug Development Center , Dana-Faber Institute
  • Daniel Speidel Co-Managing Director , Breakpoint Therapeutics

5:30 pm Chair’s Closing Remarks & End of Conference